LKT Labs

Biochemicals for Life Science Research

Tozasertib

Tozasertib

Product ID T5996
Cas No. 639089-54-6
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $60.10 In stock
25 mg $105.30 In stock
100 mg $375.60 In stock
250 mg $721.20 In stock
Bulk Quote

Quicklinks

Description

Tozasertib is an anticancer chemotherapeutic pan-aurora kinase (AurK) inhibitor that also inhibits FMS-like tyrosine kinase 3 (FLT3) and Abl. Tozasertib is currently in clinical trials as a potential treatment for acute lymphoblastic leukemia (ALL). In cellular models of cancer, tozasertib activates caspase-3 and PARP and decreases expression of HDAC, increasing apoptosis and inhibiting cell growth. In other cellular models, tozasertib inhibits cell proliferation and metastasis by blocking downstream ERK signaling and downregulating cdc25c and cyclin B. This compound also decreases tumor growth in an in vivo model of prostate cancer.

Product Info

Cas No.

639089-54-6
Purity

≥98%
Formula

C23H28N8OS
Formula Wt.

464.59
Chemical Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
IUPAC Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
Synonym

VX680, MK0457
Melting Point

245-260°C
Solubility

DMSO at 100 mg/mL
Appearance

White to pale yellow powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

T5996 MSDS PDF
Info Sheet

T5996 Info Sheet PDF

References

Okabe S, Tauchi T, Tanaka Y, et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 4;13(1):32. PMID: 23556431.

Li Y, Zhou W, Wei L, et al. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol. 2012 Dec;41(6):2139-49. PMID: 23007526.

Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. PMID: 22772060.

Jeet V, Russell PJ, Verma ND, et al. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets. 2012 Feb;12(2):144-63. PMID: 22229247.

Salah E, Ugochukwu E, Barr AJ, et al. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J Med Chem. 2011 Apr 14;54(7):2359-67. PMID: 21417343.

Oliveira TM, Ahmad R, Engh RA. VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. J Phys Chem A. 2011 Apr 28;115(16):3895-904. PMID: 21306143.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A6264

    Apramycin Sulfate

    Aminoglycoside; protein translation inhibitor. ...
    ≥98%
  • G0245

    Gallocatechin Gallate

    Polyphenol found in Camilla sinensis; HIV integ...

    ≥98%
  • L589921

    Loxapine Succinate

    D2 and D4 dopamine receptor inhibitor.

    ≥99%
  • J0379

    Jatrorrhizine Chloride

    Alkaloid compound originally found in Corydalis...

    ≥95%
  • E9317

    Exemestane

    Aromatase inhibitor.

    ≥97%
  • A5130

    Amphotericin B

    Polyene, binds ergosterol and induces membrane ...

    ≥90%
  • A5035

    5-Aminosalicylic Acid

    Salicylic acid derivative; PPARγ agonist, pote...

    ≥98%
  • C2968

    Chrysin

    Flavone found in Passiflora, Oroxylum, and Pleu...

    ≥98%
  • V1872

    Vesicular Stomatitis Virus Peptide

    Peptide fragment of VSV; LDLR agonist.

    ≥95%
  • G681019

    Grapiprant

    EP4 receptor antagonist

    ≥98%
  • T5847

    Tolvaptan

    V2 antagonist.

    ≥99%
  • H9620

    7-Hydroxyaristolochic Acid A

    Derivative of aristolochic acid found in Asarum...

    ≥95%
  • D1777

    Desmopressin Acetate

    Synthetic peptide, vasopressin derivative; V2 a...

    ≥95%
  • N5768

    Norfloxacin

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • B5075

    BMS-708163

    γ-Secretase inhibitor.

    ≥98%
  • S0501

    SB-939

    HDAC inhibitor.

    ≥98%
  • A0025

    17-Allylaminogeldanamycin

    Geldanamycin derivative; HSP90 inhibitor.

    ≥97%
  • K1776

    Ketotifen Fumarate

    H1 histamine and LT antagonist, PDE inhibitor.<...

    ≥98%
  • F0150

    Famotidine

    Histamine H2 antagonist, GSK-3β inhibitor.

    ≥98%
  • F4683

    Fluticasone Propionate

    β2-adrenergic agonist.

    ≥98%